Third Quarter 2021 Report
Oct. 15, 2021
20/20 Ranks #770 on Inc.5000 List of Fastest Growing Private Companies in America
On August 17 the Inc.5000 list of the fastest-growing private companies in America was released. Companies on the list are ranked according to percentage revenue growth from 2017 to 2020. 20/20 ranked no. 770. The press release announcing this ranking may be downloaded here.

Being on the Inc.5000 means we are among the top 0.07% of U.S. companies in terms of growth. Entities founded by Mark Cuban, Rebecca Minkoff, Daymond John, and Bill Gates made this coveted list in prior years.

Third Quarter Revenues Top $2 million Generating Company's First Profits
For the 3 month period ending in September, 20/20's revenue exceeded $2 million (unaudited) for all products compared to $321,000 during the 3rd Quarter of last year. Covid-19 PCR testing accounted for over 90% of these revenues, largely from contracts with the Health Departments of Montgomery County and the State of Maryland. Net profits exceeded $300,000 (unaudited) in our company's first profitable quarter ever.

20/20 is actively seeking new tests with near-term revenue potential to add to our portfolio to augment an eventual decline in Covid-19 testing. We believe that our CLIAx accelerator will contribute significantly towards that goal (see below).
Maryland Awards K-12 Covid Testing Contract to 20/20
In August, 20/20 was one of only five clinical laboratories awarded a contract with the Maryland Department of Health to conduct Covid-19 screening at K-12 schools throughout the state. As of this writing we are conducting PCR tests for three County public school systems and five private schools.
20/20 Stock Trading on StartEngine Secondary
Beginning on September 8, our shares have been trading on StartEngine Secondary giving interested shareholders an opportunity to sell their shares or buy additional shares in our company.
 
This new alternative trading system (ATS) is regulated by the SEC and operated by StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA. This market is open to both accredited and unaccredited investors.  
 
Listing on StartEngine Secondary permits any interested party to buy or sell 20/20 stock under certain state and local restrictions. To begin trading, please visit Secondary.StartEngine.com and follow the instructions to open an account. For more information on the process of buying or selling shares on StartEngine Secondary please contact Contact@startengine.com. 
  
Please Note: 20/20 reserves the right to forgo listing on the ATS due to (a) changes in its commercial trajectory as a result of, without limitation, its own commercial progress, that of its competitors, or changes to regulatory or economic conditions, (b) the performance of the ATS with regard to other issuers, or (c) an imminent listing on a national stock exchange such as NASDAQ. Investors should not invest in this Offering with the expectation that near-term liquidity through StartEngine Secondary or other means will be available.
 
While the company has signed a quotation agreement to trade the securities offered on StartEngine Secondary’s new alternative trading system (the “ATS”), a company which intends to be quoted on the marketplace will be subject to certain requirements which the company may or may not be able to satisfy in a timely manner. Even if a company is qualified to quote its securities on the market, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.
 
Australian Company to Launch Prostate Cancer Test through our Clinical Lab Innovation Accelerator (CLIAx)
Last month, we announced the first agreement with a start-up occupant of our new Clinical Lab Innovation Axcellerator (CLIAx). The agreement is with Australian-based Minomic International Ltd, a diagnostics firm that is gearing up to introduce MiCheck® Prostate, a blood test that uses proprietary algorithms and biomarkers to estimate the risk of aggressive prostate cancer. “Our company is so excited to be working with the CLIAx team. Their clinical lab accelerator is a unique concept that allows us to tap into the expertise in laboratory testing. It is just what Minomic requires - a ‘soft landing’ site to enter the U.S. market so we can focus on the key activity of test rollout instead of the necessary minutiae of setting up and running a lab service,” said Dr. Brad Walsh, CEO of Minomic International Ltd.

A press release announcing the launch of CLIAx and the Minomic agreement may be viewed here.

CLIAx is believed to be the first shared lab facility providing access to testing equipment and personnel that comply with federal and state regulations under the Clinical Laboratory Improvement Amendments (CLIA). A CLIAx promotional video may be viewed here and the brochure may be downloaded here. 
 
20/20 is targeting companies with tests that address a similar or complementary market to our OneTest, namely early detection and wellness, and is seeking U.S. marketing rights to these tests. Thus, in addition to effectively managing our overhead expenses CLIAx is expected to be a platform to permit 20/20 to grow its product pipeline while maintaining low to nominal R&D expenditures and risks.


OneTest Scientific Presentation wins 1st Place at Leading Lab Meeting
At the Poster Competition for the October 2021 Annual Scientific Meeting of the American Association of Clinical Chemistry (AACC) our submission was voted first place by the AACC Industry Division. The poster submitted described the latest algorithm model for 20/20's proprietary multi-cancer early detection blood test.

OneTest is only our first example of our pioneering approach to improving the accuracy and clinical value of widely used lab tests that avoids the challenges of developing new biomarkers and analyzers. By combining large quantities of real-world outcome data with the latest, most advanced machine learning techniques 20/20 has significantly improved the performance of cancer screening blood tests.

As a 1st place winner we have been invited to present a webinar to the AACC community in January that we will leverage to identify future collaborators and industry partners.

Our previous Quarterly Reports and Press Releases may be downloaded here:
Financial Reports
In order to maintain our Reg. A+ Qualification we are required to file Annual and Semiannual Reports with the U.S. Securities & Exchange Commission (SEC) that include Financial Statements (the Annual Statement must be audited). Those reports may be accessed by entering "20/20 GeneSystems, Inc." at https://www.sec.gov/edgar/searchedgar/companysearch.html or by contacting investors@2020gene.com
Regulation A Offering and Forward Looking Statements
20/20 GeneSystems is offering securities through the use of an Offering Statement that has been qualified by the Securities and Exchange Commission under Tier II of Regulation A. A copy of the Final Offering Circular that forms a part of the Offering Statement may be obtained from: https://www.sec.gov/edgar/searchedgar/companysearch.html
A QUALIFIED OFFERING ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.